Author:
Lorenzo Lopez Moira,Kearns Victoria R.,Curran Judith M.,Patterson Eann A.
Abstract
AbstractNanomedicine has the potential to increase the biostability of drugs to treat retinal diseases, improving their performance and decreasing the required number of intravitreal injections. However, accurate pharmacokinetic studies of these nanoparticle-drug conjugates, nanoparticle motion across the vitreous humour and interaction with the retinal cell layers still need to be investigated. Existing nanoparticle tracking techniques require fluorescent labels, which can impact cytotoxicity, nanoparticles’ motion, protein interactions, and cell internalization. In this study, a real-time label-free tracking technology, for single nanoparticles in an optical microscope based on the optical phenomena of caustics, was used to characterise the diffusion of nanoparticles in agar-hyaluronic acid hydrogels, previously validated as vitreous humour substitutes for in vitro models. The results demonstrated that the diffusion of nanoparticles through these hydrogels was heterogeneous, and that nanoparticle size had an important role in nanoparticle distribution across and within in vitro vitreous substitutes. These findings suggest that nanoparticle diameter is a critical parameter for designing novel therapeutics for retinal diseases. Moreover, nanoparticle charge did not affect nanoparticle diffusion or distribution in these synthetic hydrogels. The use of caustics in optical microscopy has been demonstrated to be a reproducible, inexpensive technique for screening novel therapeutics in eye in vitro models.
Funder
Doctoral Network in Technologies for Healthy Aging
Engineering and Physical Sciences Research Council
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. M. Schmoker, ‘Time to Focus’, Principal Leadership, vol. 13, no. 3, pp. 18–21, 2012, [Online]. https://www.fightforsight.org.uk/our-research/timetofocus/?gad_source=1&gclid=CjwKCAiAqY6tBhAtEiwAHeRopbFuAegQ_pW6sPvDRSMk-ArDwJ7mmt3chTaWST4jrJwcdxvAT3apchoCO6AQAvD_BwE Accessed 14 January 2024.
2. Bourne, R. R. A. et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health 9(2), e144–e160. https://doi.org/10.1016/S2214-109X(20)30489-7 (2021).
3. Wang, W. & Lo, A. C. Y. Diabetic retinopathy: Pathophysiology and treatments. Int. J. Mol. Sci. 19(6), 2018. https://doi.org/10.3390/ijms19061816 (1816).
4. Stahl, A. Diagnostik und Therapie der altersabhängigen Makuladegeneration. Dtsch Arztebl Int. 117(29–30), 513–520. https://doi.org/10.3238/arztebl.2020.0513 (2020).
5. Kim, H. M. & Woo, S. J. Ocular drug delivery to the retina: Current innovations and future perspectives. Pharmaceutics 13(1), 1–32. https://doi.org/10.3390/pharmaceutics13010108 (2021).